Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Judit Harsányi
Observed names:
Harsanyi, Judit,
Harsányi, Judit,
J. Harsanyi,
J. Harsányi
Observed institutions:
Gedeon Richter (Hungary),
Allergan (United States)
OpenAlex ID:
A5058881972
Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial
2017
·
György Németh
, István Laszlovszky
, et al.
·
The Lancet
·
374
The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors
2019
·
Wolfgang Fleischhacker
, Silvana Galderisi
, et al.
·
European Psychiatry
·
118
PDF
Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia
2019
·
Stefan Leucht
, Ágota Barabássy
, et al.
·
Neuropsychopharmacology
·
57
PDF
Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial
2025
·
Willie R. Earley
, Hua Guo
, et al.
·
Psychopharmacology Bulletin
·
45
Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia
2019
·
Christoph U. Correll
, Steven G. Potkin
, et al.
·
The Journal of Clinical Psychiatry
·
38
Cariprazine Safety in Adolescents and the Elderly: Analyses of Clinical Study Data
2020
·
Balázs Szatmári
, Ágota Barabássy
, et al.
·
Frontiers in Psychiatry
·
25
PDF
P.3.d.053 Cariprazine as monotherapy for the treatment of schizophrenia patients with predominant negative symptoms: a double-blind, active controlled trial
2015
·
M. Debelle
, G. Németh
, et al.
·
European Neuropsychopharmacology
·
14
Efficacy of cariprazine on predominant negative symptoms of patients with schizophrenia: post hoc analysis of PANSS data, Marder factors, and cognition
2016
·
S. Marder
, I. Laszlovszky
, et al.
·
European Neuropsychopharmacology
·
8
Coadministration of Cariprazine with a Moderate CYP3A4 Inhibitor in Patients with Schizophrenia: Implications for Dose Adjustment and Safety Monitoring
2024
·
Máté Szabó
, Zoltán Hujber
, et al.
·
Clinical Pharmacokinetics
·
7
PDF
Monotherapy treatment with cariprazine for the treatment of predominant negative symptoms of patients with schizophrenia: A double-blind, active comparator-controlled trial
2016
·
G. Németh
, M. Debelle
, et al.
·
European Psychiatry
·
3
PDF
Efficacy of cariprazine in the treatment of negative symptoms of schizophrenia: Post hoc analyses versus aripiprazole
2019
·
A. Barabassy
, B. Szatmári
, et al.
·
European Neuropsychopharmacology
·
2
Safety profile of cariprazine: Post hoc analysis of safety parameters of pooled cariprazine schizophrenia studies
2019
·
B. Szatmári
, A. Barabassy
, et al.
·
European Neuropsychopharmacology
·
2
Lack of Clinically Meaningful Effect of Cariprazine on the Pharmacokinetics of a Combined Oral Contraceptive
2024
·
Márta Erzsébet Rosa
, Zoltán Juhász
, et al.
·
Neurology and Therapy
·
1
PDF
P.456 Akathisia during cariprazine treatment: Post-hoc analyses of pooled schizophrenia studies
2019
·
A. Barabassy
, B. Sebe
, et al.
·
European Neuropsychopharmacology
·
1
Day-to-day and Social Functioning of Patients with Negative Symptoms of Schizophrenia: Post-hoc Analyses of a Phase 3 Clinical Trial with Cariprazine Monotherapy and Risperidone
2017
·
Á. Barabássy
, I. Laszlovszky
, et al.
·
European Psychiatry
·
1
PDF
Die kontrollierte anaerobe Nassröste als Teil eines innovativen Bioraffinerieprozesses zur Herstellung von Naturfasern und Holzersatzprodukten
2026
·
Harsanyi, Judit
, Poraj-Kobielska, Marzena
, et al.
·
OpenAgrar
Stoffliche und energetische Verwertung von Faserpflanzen mit einem neuartigen Bioraffinerieverfahren
2025
·
Kretzschmar, Jörg
, Harsányi, Judit
, et al.
·
OpenAgrar
P.0904 Results of a phase 1 trial investigating the effect of cariprazine on the pharmacokinetics of a combined oral contraceptive
2021
·
J. Harsanyi
, M. Kapás
, et al.
·
European Neuropsychopharmacology
P.388 Clinical improvement of patients with predominant negative symptoms of schizophrenia: Post-hoc analysis of cariprazine versus risperidone
2019
·
B. Sebe
, A. Barabassy
, et al.
·
European Neuropsychopharmacology
Safety profile of cariprazine in patients with predominant negative symptoms of schizophrenia
2017
·
B. Szatmári
, A. Barabassy
, et al.
·
European Neuropsychopharmacology
Cariprazine vs risperidone efficacy on predominant negative symptoms of schizophrenia: post hoc analysis of negative symptoms subdomains
2017
·
I. Laszlovszky
, A. Barabassy
, et al.
·
European Neuropsychopharmacology
Diagnosis of Predominant Negative Symptoms: Post-hoc Analyses of a Phase 3 Clinical Trial with Cariprazine Monotherapy and Risperidone
2017
·
I. Laszlovszky
, Á. Barabássy
, et al.
·
European Psychiatry
PDF
Show more works
View as search
Works count:
22
Citation count:
696
H-index:
8
I10-index:
7
Year
Topic
Type
